Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Channel Modulation in Neurodegeneration and Neuroprotection
share announcement

Channel Modulation in Neurodegeneration and Neuroprotection

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 5674

Special Issue Editor

Dr. Yan-Fang Xian

E-Mail Website
Guest Editor
School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong
Interests: Chinese medicine; pancreatic cancer; prostate cancer; herb-drug interaction; resistance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

 Ion channels are widely expressed in the central and peripheral nervous system and are crucial mediators of neuronal excitability. They play an important role in neurological and neurodegenerative conditions such as epilepsy, Parkinson’s, Huntington’s, and Alzheimer’s disease.  This Special Issue will provide a multidisciplinary platform for discussing pharmacological studies on ion channels and the implication thereof in neurodegeneration. This issue accepts original high-quality research articles that are not yet published or sought for publication. Please feel free to discuss your planned submission with the editor. Potential topics include but are not limited to the following: 

  • Therapeutic mechanism of neurodegeneration and neurodegenerative diseases;·       
  • Design and development of novel modulators of channels that may find application in neurological disorders.

Dr. Yan-Fang Xian
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 2329 KiB  
Article
In Silico and In Vitro Screening of Serine Racemase Agonist and In Vivo Efficacy on Alzheimer’s Disease Drosophila melanogaster
by Chih-Hao Lu, Hao-Teng Chang, Lee-Fen Hsu, Ming-Hsueh Lee, Jack Cheng, Dong Chuan Wu and Wei-Yong Lin
Pharmaceuticals 2023, 16(2), 280; https://doi.org/10.3390/ph16020280 - 13 Feb 2023
Cited by 2 | Viewed by 2284
Abstract
The NMDA receptor hypofunction has been implicated in schizophrenia, memory impairment, and Alzheimer’s disease. Modulating the abundance of D-serine, a co-agonist of the NMDA receptor, is a strategy to treat symptoms of the NMDA receptor hypofunction. In contrast to D-amino acid oxidase (DAAO) [...] Read more.
The NMDA receptor hypofunction has been implicated in schizophrenia, memory impairment, and Alzheimer’s disease. Modulating the abundance of D-serine, a co-agonist of the NMDA receptor, is a strategy to treat symptoms of the NMDA receptor hypofunction. In contrast to D-amino acid oxidase (DAAO) inhibitors, which aim at decreasing the loss of D-serine, this study tried to identify serine racemase (SRR) agonists, which boost the conversion of L-serine to D-serine. We used holo and apo structures of human SRR for the molecular docking against the National Cancer Institute (NCI) and ZINC compound databases and validated their efficacy by in vitro SRR activity assay. We identified NSC294149 (2-amino-3-(3-nitroimidazo[1,2-a]pyridin-2-yl)sulfanylpropanoic acid) as a potential SRR agonist and confirmed its amelioration of the hazard ratio of survival of the AD model of fruit fly (Drosophila melanogaster). These results suggest that the SRR agonist could be a drug design target against the NMDA receptor hypofunction symptoms. Full article
(This article belongs to the Special Issue Channel Modulation in Neurodegeneration and Neuroprotection)
►▼ Show Figures

Figure 1

14 pages, 2827 KiB  
Article
Antiseizure Effects of Cannabidiol Leading to Increased Peroxisome Proliferator-Activated Receptor Gamma Levels in the Hippocampal CA3 Subfield of Epileptic Rats
by Anna-Maria Costa, Fabiana Russo, Lara Senn, Davide Ibatici, Giuseppe Cannazza and Giuseppe Biagini
Pharmaceuticals 2022, 15(5), 495; https://doi.org/10.3390/ph15050495 - 19 Apr 2022
Cited by 18 | Viewed by 2936
Abstract
We evaluated the effects of cannabidiol (CBD) on seizures and peroxisome proliferator-activated receptor gamma (PPARγ) levels in an animal model of temporal lobe epilepsy (TLE). Adult male Sprague-Dawley rats were continuously monitored by video-electrocorticography up to 10 weeks after an intraperitoneal kainic acid [...] Read more.
We evaluated the effects of cannabidiol (CBD) on seizures and peroxisome proliferator-activated receptor gamma (PPARγ) levels in an animal model of temporal lobe epilepsy (TLE). Adult male Sprague-Dawley rats were continuously monitored by video-electrocorticography up to 10 weeks after an intraperitoneal kainic acid (15 mg/kg) injection. Sixty-seven days after the induction of status epilepticus and the appearance of spontaneous recurrent seizures in all rats, CBD was dissolved in medium-chain triglyceride (MCT) oil and administered subcutaneously at 120 mg/kg (n = 10) or 12 mg/kg (n = 10), twice a day for three days. Similarly, the vehicle was administered to ten epileptic rats. Brain levels of PPARγ immunoreactivity were compared to those of six healthy controls. CBD at 120 mg/kg abolished the seizures in 50% of rats (p = 0.033 vs. pre-treatment, Fisher’s exact test) and reduced total seizure duration (p < 0.05, Tukey Test) and occurrence (p < 0.05). PPARγ levels increased with CBD in the hippocampal CA1 subfield and subiculum (p < 0.05 vs. controls, Holm–Šidák test), but only the highest dose increased the immunoreactivity in the hippocampal CA3 subfield (p < 0.001), perirhinal cortex, and amygdala (p < 0.05). Overall, these results suggest that the antiseizure effects of CBD are associated with upregulation of PPARγ in the hippocampal CA3 region. Full article
(This article belongs to the Special Issue Channel Modulation in Neurodegeneration and Neuroprotection)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop